Overview and Scope
Kidney cancer drugs that can treat kidney cancer. Because they can reach cancer cells practically anywhere in the body, these treatments are known as systemic therapy. Several different types of medications may be used, depending on the type of kidney cancer. It functions by stopping tyrosine kinases, which are crucial proteins in cancer cells that aid in growth and survival, or angiogenesis, the development of new blood vessels that feed malignancies.
Sizing and Forecast
The kidney cancer drugs market size has grown strongly in recent years. It will grow from $7.81 billion in 2023 to $8.23 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increased healthcare expenditure, rapid growth in elderly population, increase in pharmaceutical r&d expenditure, and advances in cancer drug discovery.
The kidney cancer drugs market size is expected to see strong growth in the next few years. It will grow to $10.12 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing geriatric population, rise in healthcare expenditure, rise in acquisitions and partnerships for drug development, and high potential of emerging economies. Major trends in the forecast period include adopting 3d technology in manufacturing drugs and create models to provide matrix interactions and more personalized treatments, investing in biomarkers to produce more effective drugs in a smaller time frame, launching or adopting new treatment developments to treat patients and give them a longer survival time, improve treatment by offering personalized medicine, invest in ai solutions, to save drug development time and accurately diagnose a patient, and collaborating and partnering with other companies or government bodies to accelerate the development of new drugs.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report
Segmentation & Regional Insights
The kidney cancer drugs market covered in this report is segmented –
1) By Type: Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)
2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Other Products
3) By End Users: Hospitals, Clinics, Research Center, Other End-Users
North America was the largest region in the kidney cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the global kidney cancer drugs market share during the forecast period. The regions covered in the kidney cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2591&type=smp
Major Driver Impacting Market Growth
The rise in the incidence of renal cancer acts as one of the major drivers of the kidney cancer drugs market. Changes in the lifestyle of people, the consumption of tobacco, and an unhealthy diet are some factors that contribute to the growth of these renal cancer cells. For instance, in January 2022, according to the American Cancer Society, a US-based health organization that works for cancer elimination, there will be 79,000 new instances of kidney cancer diagnosed (50,290 men and 28,710 women), and 13,920 people will pass away from the disease (8,960 men and 4,960 women). The majority of people are diagnosed between the ages of 65 and 74, with an average diagnosis age of 64. When a person is under the age of 45, kidney cancer is quite rare. thus, driving the growth of the kidney cancer drugs market.
Key Industry Players
Major companies operating in the kidney cancer drugs market report are Pfizer Inc., Novartis AG, Exelixis, Inc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Bayer AG, Merck & Co., Inc., EUSA Pharma Inc., UroGen Pharma Ltd., Natco Pharma, Arlak Biotech, Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co., Ltd, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Celon Pharma, Amgen Inc ., Biocon Ltd, Rani Therapeutics, Eli Lilly and Company, Abbott Laboratories, Emisphere Technologies, Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Sanofi, Biogen Inc, AVEO Oncology, Eurofarma Laboratórios S.A., TUTEUR Argentina, Pierre Fabre Group, Celnova Pharma, Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Julphar, Novo Nordisk A/S, Kitov Pharma Limited, CureTech Ltd., Neopharma
The kidney cancer drugs market report table of contents includes:
1. Executive Summary
- Market Characteristics
- Market Trends And Strategies
- Impact Of COVID-19
- Market Size And Growth
- Segmentation
- Regional And Country Analysis
………..
- Competitive Landscape And Company Profiles
- Key Mergers And Acquisitions
- Future Outlook and Potential Analysis
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
